Mucosta oral (rebamipide oral) / Otsuka, Kubota, Dongkwang - LARVOL DELTA

Inhibition of mycobacteria proliferation in macrophages by diaryl ether derivatives of Dehydrozingerone compound and repurposed drugs (Rebamipide, Sofalcone) via NF-κB pathway inhibition. (PubMed, Tuberculosis (Edinb)) - "Our results unequivocally validate NF-κB inhibition by DHZ (6), Sofalcone, and Rebamipide as a powerful strategy for HDT. These compounds are promising adjunct therapies to suppress host inflammation and limit tissue damage."

Journal • Immunology • Infectious Disease • Inflammation • Pulmonary Disease • Respiratory Diseases • Tuberculosis • MMP2 • MMP9

Effects of rebamipide quadruple therapy with gastrointestinal endoscopy adjuvant therapy on gastrointestinal hormones in patients with gastric ulcer bleeding. (PubMed, Arab J Gastroenterol) - "Rebamipide therapy combined with gastrointestinal endoscopy is an effective treatment for gastric ulcer bleeding and demonstrates a high level of safety."

Journal • Peptic Ulcer • GAST

Rebamipide in Patients With Active Rheumatoid Arthritis (clinicaltrials.gov) - P1/2 | N=60 | Completed | Sponsor: October 6 University | Recruiting ➔ Completed | Trial completion date: Dec 2025 ➔ Sep 2025

Trial completion • Trial completion date • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology

Rebamipide Induces Hair Regeneration Through EP4-Driven Lipid Metabolism Remodeling. (PubMed, Int J Mol Sci) - "Mechanistically, computer simulations and target validation experiments confirm that rebamipide directly binds to the prostaglandin E receptor EP4, triggering PI3K/ERK-dependent autophagy and lipolysis. Collectively, our findings highlight EP4 as a novel therapeutic target for hair loss and position rebamipide as an agent that couples lipid metabolism remodeling with HFSC activation."

Journal • Alopecia • Immunology • Metabolic Disorders • Peptic Ulcer

THE EFFICACY AND SAFETY OF HIGH-DOSE DUAL THERAPY FOR HELICOBACTER PYLORI ERADICATION IN THE NORTH-WESTERN REGION OF RUSSIA (UEGW 2025) - "pylori) infection is a common problem (prevalence of 32.7% in 2023) in the North-Western Federal District, comprising one-tenth of Russia, where primary resistance rates of clarithromycin and levofloxacin are >15%.1 The eradication rates remain low and do not reach the threshold value of 95% (eradication rate of 86.8% in 2023)...Patients were randomly allocated to two eradication groups: high-dose dual therapy for 14 days (esomeprazole 40 mg and amoxicillin 1000 mg three times daily) and optimized high-dose dual therapy for 14 days (esomeprazole 40 mg, amoxicillin 1000 mg, rebamipide 100 mg three times daily)... In the North-Western region of Russia, the fourteen-day optimized high-dose dual therapy with PPI-amoxicillin-rebamipide provided encouraging results (over 90% cure rates) and had the lower incidence rate of side effects (19.8%) suggesting as an alternative for H. pylori rescue treatment in the local region."

Clinical • Infectious Disease

EFFECTIVENESS OF REBAMIPIDE SUSTAINED-RELEASE TABLETS ON SUBJECTIVE SYMPTOMS IN PATIENTS WITH GASTRITIS: A MULTI-CENTER, PROSPECTIVE, OBSERVATIONAL STUDY [WITHDRAWN] (UEGW 2025) - No abstract available

Clinical • Observational data • Gastrointestinal Disorder

3D-Printed Implant Overdentures: Comparing Impression Techniques (clinicaltrials.gov) - P=N/A | N=16 | Not yet recruiting | Sponsor: Mansoura University

New trial

Comparative Efficacy and Safety of Stillen® and Rebamipide in Patients with Acute or Chronic Gastritis: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. (PubMed, J Clin Med) - "Most studies were assessed as having a low risk of bias, and the certainty of evidence was rated as high for most efficacy outcomes. The network meta-analysis suggests that Stillen® is non-inferior to rebamipide in improving erosions in patients with acute or chronic gastritis."

Journal • Retrospective data • Review • Dyspepsia • Gastrointestinal Disorder • Pain

Repurposing of rebamipide as a neuroprotective agent to alleviate letrozole-induced depressive-like behaviors in female rats: Targeting SIRT1/FoxO1/wnt/ β-catenin, and related ferroptosis pathways. (PubMed, Life Sci) - "Reba has a major neuroprotective role via activating SIRT1 and inhibiting related oxidative, neuroinflammatory, and ferroptosis pathways."

Journal • Preclinical • CNS Disorders • Depression • Inflammation • Polycystic Ovary Syndrome • Psychiatry • CTNNB1 • GPX4 • NLRP3 • SIRT1 • SLC7A11 • TNFA

Rebamipide modulates the miR-29a/SIRT1/FoxO3a and NF-κB pathways in methotrexate-induced testicular damage. (PubMed, Eur J Pharmacol) - "Besides, REBA pretreatment potentiated the anticancer activity of METH in a mouse model of Ehrlich solid carcinoma (ESC) (histology with scoring). It was concluded that REBA protected against METH-induced testicular toxicity through modulating the miR-29a/SIRT1/FoxO3a, inflammation, and apoptosis pathways."

Journal • Oncology • Solid Tumor • CAT • FOXO3 • IL6 • MIR29A • TNFA

The high-dose dual therapy for eradication of Helicobacter pylori: efficacy and safety (PubMed, Ter Arkh) - "The efficacy of the Era-RebAmIPP regimen is comparable to conventional triple therapy with bismuth. To assess the effectiveness of this regimen, larger-scale studies are required in various regions of our country."

Clinical • Journal • Infectious Disease

Real-World Effectiveness of Rebamipide on Gastritis Symptoms: A Patient-Focused Approach. (PubMed, Clin Transl Sci) - "The symptom improvement rate (≥ 50% reduction) was 71.5% in the monotherapy group and 71.4% in the combination therapy group, with no significant difference between the two groups (p = 0.976). Rebamipide monotherapy provided similar levels of GI symptom relief compared to combination therapy with PPIs in a real-world clinical setting."

Journal • Observational data • Real-world evidence • Gastrointestinal Disorder

Mosapride combined with rebamipide demonstrates superior efficacy for treatment of chronic atrophic gastritis. (PubMed, Am J Transl Res) - "The combination of mosapride and rebamipide offers superior efficacy in managing CAG without increasing adverse effects. It significantly improves pathological conditions, expedites symptom resolution, and enhances gastric mucosal biomarker profiles, supporting its broader clinical application."

Journal • Addiction (Opioid and Alcohol) • Gastrointestinal Disorder • EGF

Rebamipide in Patients With Active Rheumatoid Arthritis (clinicaltrials.gov) - P1/2 | N=50 | Recruiting | Sponsor: October 6 University | Trial completion date: Nov 2024 ➔ Dec 2025 | Trial primary completion date: Oct 2024 ➔ Oct 2025

Trial completion date • Trial primary completion date • Immunology • Inflammatory Arthritis • Rheumatoid Arthritis • Rheumatology

Drug treatment strategies for erosive esophagitis in adults: a narrative review. (PubMed, Transl Gastroenterol Hepatol) - "Search terms encompassed various treatment modalities including PPIs, potassium-competitive acid blockers (P-CABs), histamine 2 receptor antagonists (H2RAs), sucralfate, prokinetics, rebamipide and alginates...Among PPIs, esomeprazole shows slightly better healing outcomes compared to others...The addition of nighttime to bedtime H2RAs or use of double PPI dose may benefit refractory cases. Further studies are needed to directly compare PPIs and P-CABs in different EE grades and evaluate the value of adjunctive therapies."

Journal • Review • Gastroenterology • Gastroesophageal Reflux Disease • Gastrointestinal Disorder

Comparison of rebamipide and tegoprazan combination therapy and tegoprazan monotherapy for ESD induced gastric ulcers a randomized multicenter study. (PubMed, Sci Rep) - "The proportion of flat ulcer scar at week 8 was significantly higher in the combination group than in the tegoprazan monotherapy group (73.8% vs. 48.4%, P = 0.007). Combination treatment with rebamipide and tegoprazan led to faster ulcer healing and the development of high-quality post-ESD scars compared to tegoprazan monotherapy."

Clinical • Journal • Monotherapy • Gastric Cancer • Oncology • Peptic Ulcer

Comparative Efficacy of Treatments for Radiation-Induced Oral Mucositis in Patients With Head and Neck Cancer. (PubMed, Cureus) - "In contrast, rebamipide and benzydamine had higher complication rates (25% and 28%, respectively) and less significant symptom relief. Given its safety, efficacy, and minimal side effects, omega-3 nanoemulgel should be considered a first-line preventive treatment for oral mucositis in patients with head and neck cancer."

Journal • Review • Head and Neck Cancer • Mucositis • Oncology • Oral Cancer • Pain • Solid Tumor • Stomatitis

The Effects of Outdoor Activity on Patient-Reported Visual Outcomes Under Perioperative Management Using Cyclosporine and Rebamipide. (PubMed, Diagnostics (Basel)) - "No difference in ocular surface parameters can be attributed to the perioperative management using cyclosporine and rebamipide. CVFQ may be a useful tool for assessing subjective visual outcomes after cataract surgery."

Journal • Cataract • Ophthalmology

Unveiling the Polypharmacological Potency of FDA-Approved Rebamipide for Alzheimer's Disease. (PubMed, Pharmaceuticals (Basel)) - " The comprehensive in silico investigation highlights Rebamipide as a promising multitargeted therapeutic candidate for Alzheimer's disease. Its ability to modulate multiple pathogenic pathways simultaneously underscores its potential utility; however, these computational findings warrant further experimental validation to confirm its efficacy and therapeutic relevance in AD."

FDA event • Journal • Alzheimer's Disease • CNS Disorders • Gastroenterology • Gastrointestinal Disorder

Rebamipide Attenuates Lupus Nephritis by Enhancing Antioxidative Defense in Podocytes: Evidence from a Lupus-Prone Mouse Model. (PubMed, Int J Mol Sci) - "Similarly, in vitro treatment of murine immune cells and podocytes with rebamipide replicated its immunoregulatory and antioxidative effects. Rebamipide is proposed as a potential therapeutic candidate for managing renal involvement in SLE through its antioxidative effects on podocytes."

Journal • Preclinical • Glomerulonephritis • Immunology • Inflammation • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology • Rheumatology • Systemic Lupus Erythematosus

EFFICACY OF REBAMIPIDE IN THE PREVENTION OF NSAID-INDUCED GASTROINTESTINAL MUCOSAL BREAKS: A SYSTEMATIC REVIEW AND META-ANALYSIS. (PubMed, Am J Gastroenterol) - "Rebamipide is effective in preventing NSAID-induced gastrointestinal mucosal breaks. Rebamipide may also be as good as the standard PPIs in preventing NSAID-induced gastrointestinal mucosal breaks, and hence may be an alternative especially in those with contraindications to long term PPI use."

Journal • Retrospective data

Rebamipide (Mucosta®), a clinically approved drug, alleviates neuroinflammation and dopaminergic neurodegeneration in a Parkinson's disease model. (PubMed, J Neuroinflammation) - "Considering its established clinical use, this study supports repurposing rebamipide for treating PD and other NLRP3 inflammasome-driven neuroinflammatory diseases."

Journal • CNS Disorders • Inflammation • Movement Disorders • Parkinson's Disease • IL1B • NLRP3

Pharmacovigilance analysis of small bowel bleeding associated with NSAIDs. (PubMed, Ther Adv Drug Saf) - "PPIs did not show a significant impact on NSAIDs-associated small bowel bleeding, while rebamipide and probiotics may exhibited a preventive effect against NSAIDs-associated small bowel bleeding. Older adults and males constituted risk factors for aspirin-associated small bowel bleeding."

Adverse events • Journal

Beneficial Effect of Rebamipide Eye Drops on Blue Light-Induced Oxidative Damage in the Ocular Surface. (PubMed, J Ocul Pharmacol Ther) - "The mice were randomly divided into 5 groups: 1 untreated and 4 groups receiving BL exposure ± different topical treatments: BL exposure alone, carboxymethylcellulose, 5% N-acetylcysteine, and REB. Hematoxylin and eosin staining showed preservation of corneal epithelial thickness. Rebamipide alleviated BL-induced oxidative damage to ocular surfaces by reducing ROS levels, inhibiting apoptosis, and suppressing inflammatory cytokine expression."

IO biomarker • Journal • Ocular Inflammation • Oncology • BAX • IL6 • TNFA

A Phase 2, Multi-Center, Randomized, Double-Blind, Parallel-Group Trial to Evaluate the Efficacy and Safety of CKD-495 in Patients With Acute and Chronic Gastritis. (PubMed, Can J Gastroenterol Hepatol) - P2 | "The groups received either 75 mg or 150 mg of CKD-495, 100 mg of rebamipide, 60 mg of Artemisiae argyi folium 95% ethanol ext...These results demonstrate that 75 mg of CKD-495 has excellent efficacy for the treatment of endoscopic and symptomatic improvements for acute and chronic gastritis. Trial Registration: ClinicalTrials.gov identifier: NCT03437785."

Clinical • Journal • P2 data • Gastrointestinal Disorder • Hematological Disorders